On May 27, 2026, NewcelX Ltd. announced that it submitted a Pre-IND package to the FDA for NCEL-101, aimed at treating Type 1 Diabetes. This filing is significant for the company's future prospects.
AI Assistant
NEWCELX LTD
2026
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.